At Aquila, we understand investigating the MOA of your compound using an in vivo model is a requirement on your route to clinic. We have a range of in vivo and ex vivo platforms which can be leveraged to study the effect of your drug candidate in an inflammatory environment.
We work closely with you to select the most suitable approach based on the immune cells or disease of interest to better understand your compound or biologic.
Our customisable models can study but are not limited to the following:
- Antigenic challenge
- Autoimmune inflammation of the CNS (EAE)
- Delayed-type hypersensitivity (DTH)
- Macrophage biology
- Liver disease
We offer standard and tailored readouts ensuring robust MOA interrogation of your drug candidate. Our histology experts offer standard H&E for histological analysis through to specialist multiplex immunofluorescent staining, and our immunology expertise allows for tailored FACS analysis, ELISA, qPCR and NGS readouts.
Contact us to find out how we can support your inflammation research.